OBSTETRIC PERFORMANCE IN PATIENTS WITH THE LUPUS ANTICOAGULANT AND/OR ANTICARDIOLIPIN ANTIBODIES

被引：20

作者：

LANDY, HJ

KESSLER, C

KELLY, WK

WEINGOLD, AB

机构：

[1] Department of Obstetrics and Gynecology, Division of Hematology, Department of Internal Medicine, The George Washington University Medical Center, Washington, DC

来源：

AMERICAN JOURNAL OF PERINATOLOGY | 1992年 / 9卷 / 03期

关键词：

D O I：

10.1055/s-2007-999308

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Antiphospholipid antibodies, notably the lupus anticoagulant and anticardiolipin antibodies, are associated with recurrent fetal wastage, pregnancy complications, and thromboses. Aggressive medical treatment using aspirin and steroids has been recommended. Fifty-one patients with antiphospholipid antibodies, only four with underlying connective tissue disorders, were followed through 53 pregnancies. Aggressive therapy was used in 33 pregnancies, 90.9% of which resulted in successful obstetric outcomes, a highly statistically significant difference compared with previous pregnancies in the same patients. Most pregnancies among nine patients receiving single-agent therapy (aspirin or steroids alone) and eight patients not treated also had successful outcomes. A 48.6% complication rate was found in association with therapy, particularly gestational diabetes mellitus. There was no statistical correlation between dose or duration of therapy and development of treatment-related complications. Although a subgroup of patients with antiphospholipid antibodies will benefit from aggressive therapy, the high complication rate warrants close observation.

引用

页码：146 / 151

页数：6

共 16 条

[1]

Branch D.W., Scott J.R., Kochenour N.K., Hershgold E., Obstetric complications associated with the lupus anticoagulant, N Engl J Med, 313, pp. 1322-1326, (1985)

[2]

Lubbe W.F., Butler W.S., Palmer S.J., Liggins G.C., Lupus anticoagulant in pregnancy, Br J Obstet Gynaecol, 91, pp. 357-363, (1984)

[3]

Lockshin M.D., Druzin M.L., Goei S., Qamar T., Magid M.S., Jovanovic L., Ferenc M., Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus, N Engl J Med, 313, pp. 152-156, (1985)

[4]

Derue G.J., Englen H.J., Harris E.N., Gharavi A.E., Morgan S.H., Hull R.G., Fetal loss in systemic lupus: Association with anticardiolipin antibodies, J Obstet Gynaecol, 5, pp. 207-209, (1985)

[5]

Scott J.R., Rote N.S., Branch D.W., Immunologic aspects of recurrent abortion and fetal death, Obstet Gynecol, 70, pp. 645-656, (1987)

[6]

Lubbe W.F., Butler W.S., Palmer S.J., Liggins G.C., Fetal survival after prednisone suppression of maternal lupus-anticoagulant, Lancet, 1, pp. 1361-1366, (1983)

[7]

Lubbe W.F., Liggins G.C., Lupus anticoagulant and pregnancy, Am J Obstet Gynecol, 153, pp. 322-327, (1985)

[8]

Carreras L.O., Perez G.N., Vega H.R., Casavilla F., Lupus anticoagulant and recurrent fetal loss: Successful treatment with gammaglobulin, Lancet, 2, (1988)

[9]

Wapner R.J., Cowchock F.S., Shapiro S.S., Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions, Am J Obstet Gynecol, 161, pp. 1271-1272, (1989)

[10]

Isada H., Kessler C., Larsen J., Weingold A., Successful pregnancy after pharmacologic suppression of a circulating anticoagulant in a woman with previous pregnancy losses and pulmonary emboli: A case report, J Reprod Med, 32, pp. 221-224, (1987)

← 1 2 →